In preclinical studies, NI-1701 triggered potent antibody-dependent cellular phagocytosis (ADCP) and cytotoxicity (ADCC) of tumor B cells in vitro, through co-engagement of CD47 and CD19, and controlled tumor progression of B-cell lymphoma and leukemia xenograft models [24]. This evidence concerns the gene CD19 and neoplasm.